Erin D. Michos, MD, MHS

Articles by Erin D. Michos, MD, MHS

New Guidance in Lowering LDL-C

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 7th 2023

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

LDL-C and Cardiovascular Disease Risk

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 7th 2023

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.

Barriers and Solutions for Lipid Management in Clinical Practice

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

Multidisciplinary/Team Based Approach for Lipid Management

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 2nd 2022

Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

Emerging Therapies for Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC

December 2nd 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

The Role of Combination Therapy in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

Managing ASCVD in Patients With Statin Intolerance

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Guideline Recommendations for Lipid Lowering

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Use of Statins in Management of Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Achievement of LDL-C Goals in the Real World

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 28th 2022

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

Achievement of Goals in ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 28th 2022

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Personalized Treatment for Patients with ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 21st 2022

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Impact of Lipid Lowering on Risk for ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 21st 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

Risk Enhancing Factors in ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 14th 2022

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 14th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

Future Directions for the Treatment of ASCVD and Hypercholesterolemia

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

June 6th 2022

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Emerging Agents for Treatment of Hypercholesterolemia and ASCVD

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

June 6th 2022

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

ASCVD and Hypercholesterolemia: Patient Selection for Bempedoic Acid

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

June 6th 2022

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Safety and Efficacy of Bempedoic Acid for ASCVD and Hypercholesterolemia

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 30th 2022

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

ASCVD and Hypercholesterolemia: Combination Therapy and Statin Intolerance

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 30th 2022

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Role of Icosapent Ethyl in Managing ASCVD and Other Lipid Disorders

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 23rd 2022

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Older Agents to Manage ASCVD and Hypercholesterolemia

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 23rd 2022

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

Bempedoic Acid to Manage ASCVD and Hypercholesterolemia

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 16th 2022

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.

Managing ASCVD and Hypercholesterolemia: Statins, Ezetimibe, and PCSK9 Inhibitors

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 16th 2022

Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.

Implementing Lifestyle Modifications for ASCVD and Hypercholesterolemia Management

ByYehuda Handelsman, MD,Matthew J. Budoff, MD,Christie Ballantyne, MD,Erin D. Michos, MD, MHS,Paul S. Jellinger, MD, MACE

May 9th 2022

Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.

Erin D. Michos, MD, MHS

Articles by Erin D. Michos, MD, MHS

New Guidance in Lowering LDL-C

LDL-C and Cardiovascular Disease Risk

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

Barriers and Solutions for Lipid Management in Clinical Practice

Multidisciplinary/Team Based Approach for Lipid Management

Emerging Therapies for Hypercholesterolemia

The Role of Combination Therapy in Hypercholesterolemia

Managing ASCVD in Patients With Statin Intolerance

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

Guideline Recommendations for Lipid Lowering

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

Use of Statins in Management of Hypercholesterolemia

Achievement of LDL-C Goals in the Real World

Achievement of Goals in ASCVD

Personalized Treatment for Patients with ASCVD

Impact of Lipid Lowering on Risk for ASCVD

Risk Enhancing Factors in ASCVD

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

Future Directions for the Treatment of ASCVD and Hypercholesterolemia

Emerging Agents for Treatment of Hypercholesterolemia and ASCVD

ASCVD and Hypercholesterolemia: Patient Selection for Bempedoic Acid

Safety and Efficacy of Bempedoic Acid for ASCVD and Hypercholesterolemia

ASCVD and Hypercholesterolemia: Combination Therapy and Statin Intolerance

Role of Icosapent Ethyl in Managing ASCVD and Other Lipid Disorders

Older Agents to Manage ASCVD and Hypercholesterolemia

Bempedoic Acid to Manage ASCVD and Hypercholesterolemia

Managing ASCVD and Hypercholesterolemia: Statins, Ezetimibe, and PCSK9 Inhibitors

Implementing Lifestyle Modifications for ASCVD and Hypercholesterolemia Management

Trending on HCPLive

OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity

A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease

Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib

CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

Red Flags for Misdiagnosed Type 2, When to Order Antibodies and C‑Peptide